EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

Ragha V Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A Wood, Bruce S Bochner, Donald W MacGlashan, Melanie C Dispenza

Journal of Clinical Investigation · 15.08.2023 · 133 (16)

DOI: 10.1172/jci172335 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.08.2023. Verfasst von Ragha V Suresh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Medicine. Hauptthemen laut MEDLINE: Anaphylaxis, Peanut Hypersensitivity. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUNDIgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies. Bruton's tyrosine kinase (BTK) is an essential enzyme for IgE-mediated signaling pathways and is an ideal pharmacologic target to prevent allergic reactions. In this open-label trial, we evaluated the safety and efficacy of acalabrutinib, a BTK inhibitor that is FDA approved to treat some B cell malignancies, in preventing clinical reactivity to peanut in adults with peanut allergy.METHODSAfter undergoing graded oral peanut challenge to establish their baseline level of clinical reactivity, 10 patients had a 6-week rest period, then received 4 standard doses of 100 mg acalabrutinib twice daily and underwent repeat food challenge. The primary endpoint was the change in patients' threshold dose of peanut protein to elicit an objective clinical reaction.RESULTSAt baseline, patients tolerated a median of 29 mg of peanut protein before objective clinical reaction. During subsequent food challenge on acalabrutinib, patients' median tolerated dose significantly increased to 4,044 mg (range 444-4,044 mg). 7 patients tolerated the maximum protocol amount (4,044 mg) of peanut protein with no clinical reaction, and the other 3 patients' peanut tolerance increased between 32- and 217-fold. 3 patients experienced a total of 4 adverse events that were considered to be possibly related to acalabrutinib; all events were transient and nonserious.CONCLUSIONAcalabrutinib pretreatment achieved clinically relevant increases in patients' tolerance to their food allergen, thereby supporting the need for larger, placebo-controlled trials.TRIAL REGISTRATIONClinicalTrials.gov NCT05038904FUNDINGAstraZeneca Pharmaceuticals, the Johns Hopkins Institute for Clinical and Translational Research, the Ludwig Family Foundation, and NIH grants AI143965 and AI106043.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisPeanut HypersensitivityAdultHumansAgammaglobulinaemia Tyrosine KinaseBenzamidesPyrazinesAllergensArachis

Stichwörter der Autor:innen

AllergyBasophilsImmunologyMast cells

Substanzen

acalabrutinibAgammaglobulinaemia Tyrosine KinaseBenzamidesPyrazinesAllergens

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Department of Medicine.
  • Division of General Internal Medicine, Department of Medicine, and.
  • Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • AstraZeneca Pharmaceuticals, LP
  • Ludwig Family Foundation

Zitieren

APA

Suresh, R. V., Dunnam, C., Vaidya, D., Wood, R. A., Bochner, B. S., MacGlashan, D. W., & Dispenza, M. C. (2023). A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis. Journal of Clinical Investigation, 133(16). https://doi.org/10.1172/jci172335

Vancouver

Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW, et al. A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis. Journal of Clinical Investigation. 2023;133(16). doi:10.1172/jci172335

BibTeX
@article{Suresh2023,
  author = {Suresh, Ragha V and Dunnam, Collin and Vaidya, Dhananjay and Wood, Robert A and Bochner, Bruce S and MacGlashan, Donald W and Dispenza, Melanie C},
  title = {A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {16},
  doi = {10.1172/jci172335}
}
Kostenlos starten →